Bristol Myers Squibb accelerates clinical trials by months with Workbench AI platform
“Bristol Myers Squibb accelerates clinical trials by months with Workbench AI platform” documents a Clinical Trials & Research deployment in Pharmaceutical & Life Science at Bristol Myers Squibb. www.accenture.com reports user adoption growth: Under 100 to nearly 900 users in 3 months; this directory has not independently verified that result.
Evidence at a glance
- Evidence status:
- Automated evidence gate passed
- Deployment timeframe:
- Not reported by source
- Reported outcome metrics:
- 3 cited below
- Directory entry published:
- Source link checked:
The source-link check confirms reachability, not independent re-verification of every claim.
Source-reported figures — cited source: www.accenture.com
The Challenge
Phase III clinical trials cost between $19 million and over $100 million per trial and involve complex logistics across partners and sites. BMS needed to reduce development timelines and costly inefficiencies to bring breakthrough therapies to patients faster.
The Solution
In partnership with Accenture, BMS implemented over 30 generative AI solutions across R&D, Global Product Development & Supply, and Commercialization. The centerpiece is 'Workbench,' a clinical trial accelerator that fuses AI-driven insights with real-time operational data, delivers role-based recommendations, anticipates issues, and captures institutional knowledge across trial teams.
Results
The approach accelerated BMS clinical trials by months and increased reaction speed to prevent issues. The platform was adopted by over 30 top-priority clinical trial teams and became BMS's official platform for priority trials, standardizing best practices across the organization.
Key Takeaways
- Generative AI integrated with real-time operational data can compress Phase III clinical trial timelines by months at scale.
- Role-contextual, personalized platforms drive rapid adoption — users grew 9x in just three months without mandated rollout.
- AI platforms that capture and forward institutional knowledge help large organizations maintain execution consistency across distributed trial teams.
Explore Related
Details
- Industry
- Pharmaceutical & Life Science
- Use Case
- Clinical Trials & Research
- AI Technology
- Large Language Models & Generative AI
- Company Size
- Enterprise
- Company
- Bristol Myers Squibb
- Evidence status
- Automated evidence gate passed
- Deployment timeframe
- Not reported by source
- Directory entry published
- Source link checked
Cited source
www.accenture.comHave a similar implementation?
Share your customer's AI results and link it to your vendor profile.
Submit a case study →